IO Frontiers World 2019


Stephen Cary

Dr Stephen Cary

CEO, Omniox

Stephen Cary is the co-founder and CEO of Omniox, and co-inventor of the H-NOX technology. Stephen identified H-NOX as a potential therapeutic platform while working at the University of California, Berkeley. He secured the first financial support for Omniox by winning the inaugural Rogers Family Foundation "Bridging the Gap" Award at QB3. Subsequently, Stephen and his team obtained multiple NIH SBIR awards and a Wellcome Trust Translation Award to build Omniox' operations and enable development of the H-NOX platform.

Prior to launching Omniox, Stephen worked at Genentech in Market Strategy, and before that in Immunology Research. He participated extensively in early stage development projects, concentrating on strategic processes of transitioning therapeutic candidates from late-stage research to early development, and provided market and endpoint inputs into design of clinical trials. Stephen obtained his PhD in Biological Chemistry with Michael Marletta at the University of Michigan, and his Bachelor of Science degree in Molecular Biophysics & Biochemistry at Yale University.

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy